David Scott Jones - Feb 9, 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
SVP & Chief Commercial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Feb 9, 2023
Transactions value $
-$12,327
Form type
4
Date filed
2/13/2023, 04:02 PM
Previous filing
Jan 10, 2023
Next filing
Jun 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +4.97K +27.41% $0.00 23.1K Feb 9, 2023 Direct F1
transaction EYPT Common Stock Options Exercise $0 +5K +21.66% $0.00 28.1K Feb 9, 2023 Direct
transaction EYPT Common Stock Tax liability -$6.18K -1.48K -5.28% $4.17 26.6K Feb 9, 2023 Direct F2
transaction EYPT Common Stock Tax liability -$6.14K -1.47K -5.54% $4.17 25.1K Feb 9, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -5K -33.33% $0.00 10K Feb 9, 2023 Common Stock 5K $0.00 Direct F3
transaction EYPT Restricted Stock Units Options Exercise $0 -4.97K -50% $0.00 4.97K Feb 9, 2023 Common Stock 4.97K $0.00 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 825 shares acquired on July 31, 2022 and 1,698 shares acquired on January 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of their withholding right following the vesting of the restricted stock units.
F3 The restricted stock units vest in three annual installments beginning February 9, 2023.
F4 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.